AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 121 min read$SOPH

HC Wainwright & Co. reiterates Buy rating on Sophia Genetics, $14 price target

HC Wainwright & Co. reiterated a Buy rating and $14 price target for Sophia Genetics, implying 88.9% upside from the Oct 9 close. The firm cited strong U.S. revenue growth potential and innovative oncology applications as key drivers.

Original reporting
tradingview.com
Published Oct 12, 2026, 11:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Sophia Genetics, $14 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$SOPHBullishMed
01

Why it matters

The reiterated Buy and $14 target suggest a bullish outlook, potentially prompting short‑term buying.

02

Market read

New analyst rating provides a fresh catalyst for SOPH, likely influencing its near‑term price action.

03

What to watch

Potential regulatory hurdles and competition from larger diagnostics firms.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst note from HC Wainwright highlighting revenue growth and oncology applications for SOPH.

Company-level read

Ticker impact

$SOPHBullishHigh confidence
Context

HC Wainwright reiterated a Buy rating on SOPH with a $14 price target, implying 88.9% upside.

Expected impact

likely upward pressure as investors price in the new target

Evidence & confidence

The fresh Buy rating and near‑double price target provide a concrete catalyst for short‑term demand.

Market effects

Sector

May boost sentiment for genomics and AI‑driven diagnostics peers.

Regional

Limited to biotech/health‑tech investors, primarily US and European markets.

Global

Modest; affects niche biotech segment rather than broad indices.

Counterpoint

What could challenge this read

Target may be overly optimistic given early‑stage revenue base.

Key entities

  • analyst
    HC Wainwright & Co.

    Equity research firm issuing the rating.

  • company
    Sophia Genetics

    Genomics data analytics firm listed on Nasdaq (SOPH).

Read at source← All news

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q2 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SEC EDGAR 6-K2 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min